EQS-Ad-hoc: CompuGroup Medical SE & Co. KGaA / Key word(s): Tender Offer CompuGroup Medical SE & Co. KGaA (Company) confirms that the Company and the shareholder group around the founding family Gotthardt are in advanced discussions with the private equity firm CVC Capital Partners plc (CVC) regarding a potential conclusion of an investment agreement for the submission of a voluntary public tender offer to the shareholders of the Company. The discussions also include a later delisting of shares of the Company from the regulated market. Starting point is a potential offer price of EUR 22.00 per share that CVC has indicated to the Company in the event of a public tender offer, which is subject, in particular, to final board decisions and the signing of transaction documents.
In the event of the potential transaction being implemented, the shareholder group around the Gotthardt family intends to remain invested in the Company to the same extent as before, with around 50,1% and, subject to the outcome of the ongoing discussions, to establish a strategic partnership with CVC. The Company will inform the public and the capital market about further relevant developments in accordance with the legal requirements. End of Inside Information
08-Dec-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | CompuGroup Medical SE & Co. KGaA |
Maria Trost 21 | |
56070 Koblenz | |
Germany | |
Phone: | +49 (0)160 3630362 |
Fax: | +49 (0)261 8000 3200 |
E-mail: | investor@cgm.com |
Internet: | www.cgm.com |
ISIN: | DE000A288904 |
WKN: | A28890 |
Indices: | SDAX, TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 2046393 |
End of Announcement | EQS News Service |
|
2046393 08-Dec-2024 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.